Haleon is the new Consumer Healthcare company, independent of GSK (GlaxoSmithKline). With a portfolio of globally renowned brands such as Sensodyne, Voltaren, Panadol and Centrum and annual sales of around £ 10 billion, the company is gearing up for a premium listing on the London Stock Exchange.

Headquartered in Weybridge, UK, the new name will be found in more than 100 countries where GSK Consumer Healthcare operates. The separation of the two companies will be managed by transferring at least 80 percent of the shares held by GSK to the shareholders of the new company.

“Introducing Haleon to the world marks another step in our journey to become a new, standalone company. Our name is grounded in our purpose to deliver better everyday health with humanity and to be a world-leader in consumer healthcare. We are on track to launch Haleon in mid-2022 and our business momentum is strong. We look forward to updating investors and analysts more on this at our capital markets event at the end of February,” said Brian McNamara, Chief Executive Officer Designate, Haleon.

“Haleon brings to life years of hard work by many outstanding people to build this new company purely dedicated to everyday health. Haleon has enormous potential to improve health and wellbeing across the world with strong prospects for growth, and through listing will unlock significant value for GSK shareholders,” said Emma Walmsley, Chief Executive Officer, GSK.